Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* weight (kilos) over 40 kg~* height (centimeters) over 155 cm~* non-anemic~* indication for primary TKA (total knee arthroplasty)~Exclusion Criteria:~* history of asthma~* peptic ulcer~* severe hepatic or renal dysfunction~* neuropathies~* bleeding disorders~* uncooperative~* drug abuse~* sensibility to etoricoxib~* paracetamol or morphine~* long acting nonsteroidal antiinflammatory drugs (NSAID) in the last 4 days preoperative~* cerebrovascular and peripheric vascular disease~* arterial hypertension (HTA) not adequately controlled~* congestive heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group ETORICOXIB PREOP (Type: EXPERIMENTAL): Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
- Group ETORICOXIB POSTOP (Type: EXPERIMENTAL): Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
- Group PLACEBO (Type: PLACEBO_COMPARATOR): 1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).